08:56 AM EDT, 06/26/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Wednesday the US Food and Drug Administration has cleared its investigational new drug application and granted a fast-track designation for the combination of its drug candidates tobevibart and elebsiran to treat chronic hepatitis D infection.

Both drug candidates are currently being evaluated in the company's phase 2 study, data from which is expected in Q4.

The FDA's fast track designation facilitates the development and expedites the review of drugs that treat severe conditions and fill an unmet medical need.

Price: 9.31, Change: +0.09, Percent Change: +1.00